Drug intelligence / Profile preview

levobupivacaine + tramadol

Development stage: Unknown
Lead developer: Endo International
Modality: Small Molecules
Administration: Caudal, Local Infiltration, Perineural, Epidural, Intrathecal

Overview

A combination of levobupivacaine, a local anesthetic agent, and tramadol, a synthetic opioid with local anesthetic properties. This combination is used for local or regional anesthesia and postoperative pain management. The combination provides synergistic analgesic effects, with levobupivacaine blocking sodium channels to prevent nerve impulse propagation while tramadol works through both opioid (weak μ-receptor affinity) and non-opioid mechanisms (inhibition of noradrenaline and serotonin reuptake).

Targets

SERT (Sodium-dependent serotonin transporter)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on levobupivacaine + tramadol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on levobupivacaine + tramadol.

Explore the full profile